Evgen is a virtual pharmaceutical company focused on the development of a synthetic version of a natural product, sulforaphane, which is known to modulate key signalling pathways involved in cellular protection and inflammation. Evgen’s proprietary technology, Sulforadex, creates new and stable variants of sulforaphane, enabling it to be used as a therapeutic for the first time. Its lead candidate, SFX-01, has entered Phase II clinical trials for both subarachnoid haemorrhage (SAH) and ER+ metastatic breast cancer with an expected read out of results in 1H 2018.
29 Nov 2016
Harnessing the clinical potential of sulforaphane
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Harnessing the clinical potential of sulforaphane
Evgen Pharma Plc (EVG:LON) | 0.8 0 0.0% | Mkt Cap: 3.31m
- Published:
29 Nov 2016 -
Author:
Martin Hall -
Pages:
44
Evgen is a virtual pharmaceutical company focused on the development of a synthetic version of a natural product, sulforaphane, which is known to modulate key signalling pathways involved in cellular protection and inflammation. Evgen’s proprietary technology, Sulforadex, creates new and stable variants of sulforaphane, enabling it to be used as a therapeutic for the first time. Its lead candidate, SFX-01, has entered Phase II clinical trials for both subarachnoid haemorrhage (SAH) and ER+ metastatic breast cancer with an expected read out of results in 1H 2018.